In Brief
Unbiased proteomics reveals multiple molecular changes at hippocampal synapses that occur prior to neurodegeneration in a taupathy/ Alzheimer's disease mouse model. Complement C1q labels phospho-Taucontaining synapses and drives microglia-mediated synapse loss that can be rescued by a C1q-blocking antibody.
INTRODUCTION
Synapse loss is a hallmark of Alzheimer's disease (AD) and other tauopathies and is central to the neurodegenerative process (Spires-Jones and Hyman, 2014) . AD is a progressive neurodegenerative disease characterized by extracellular deposits of amyloid-beta (Ab) and intracellular aggregates of abnormally phosphorylated Tau. While amyloid pathology appears long before AD symptoms manifest, it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014) . Normally, Tau is enriched in axons, where it interacts with microtubules (MTs) and may regulate MT polymerization and dynamics, axonal outgrowth, and transport (Wang and Mandelkow, 2016) . During progression of AD and other tauopathies, abnormally phosphorylated forms of Tau aggregate and accumulate in the somatodendritic compartment in neurons and can localize to synapses (Ittner and Gö tz, 2011; Tai et al., 2012) . Although Tau has been observed in dendritic spines under physiological conditions (Frandemiche et al., 2014; Morris et al., 2015) , infiltration of pathological Tau can disrupt synaptic functions and lead to synapse loss (Hoover et al., 2010; Zhao et al., 2016) .
Despite mounting evidence that the presence of abnormal Tau is synaptotoxic (Hoover et al., 2010; Ittner et al., 2010; Zhao et al., 2016) , it is not clear how Tau pathology leads to synaptic dysfunction and loss. One possibility is that pathogenic Tau may impair MT-based transport by interfering with kinesin motors (Dixit et al., 2008) or induce microtubule severing (Zempel et al., 2013) , thereby hindering cargo delivery to the spine (Hoover et al., 2010) . Another possibility is disrupted synaptic structure. The postsynaptic density (PSD) of excitatory synapses is usually located on dendritic spines, whose growth and stability depend on the actin cytoskeleton and whose dynamic modulation is essential for synaptic integrity and plasticity (Fukazawa et al., 2003; Okamoto et al., 2004) . In AD, neuronal actin regulation might be disturbed by Tau binding and crosslinking of actin, leading to the formation of cytoplasmic bundles of filamentous actin (Fulga et al., 2007) .
While neuron-autonomous disruption of synaptic composition and/or structure may contribute to synapse loss caused by Tau pathology, recent evidence in various neurodegenerative models points to an important role for synapse loss via microglial phagocytosis (Hong et al., 2016a; Lui et al., 2016; Vasek et al., 2016) . Microglia-mediated synapse pruning is implicated in normal brain development (Hong et al., 2016b; Paolicelli et al., 2011) and involves the classical complement pathway, a part of the innate immune system that facilitates the clearance of microbes and damaged cells by phagocytes (Schafer et al., 2012; Stephan et al., 2012; Stevens et al., 2007) . This developmental process of synapse elimination might be reactivated in the diseased brain (Hansen et al., 2018; Salter and Stevens, 2017) . In particular, C1q, the initiator of the classical complement pathway, which is produced by microglia in the brain, colocalizes with synaptic markers and may contribute to synapse loss in several neurodegenerative models (Hong et al., 2016a; Lui et al., 2016; Vasek et al., 2016) .
An unbiased examination of the effects of Tau pathology on the protein composition of synapses has not been performed. To precisely and broadly probe the molecular basis of Tau-mediated synaptic disruption, we conducted unbiased quantitative proteomics of PSD fractions in a widely used tauopathy model (hTau-P301S transgenic mice) at an early stage of disease progression before overt neurodegeneration. We identified significant alterations in a variety of proteins and pathways in PSDs from Tau-P301S mice. Pathway analysis combined with molecular experiments highlight the specific depletion of postsynaptic GTPase-regulating proteins and dysregulation of the actin cytoskeleton as a pathological mechanism of dendritic spine loss. Strikingly, the extracellular protein complement component C1q was markedly increased in PSDs of Tau-P301S mice (as well as in AD patients) and correlated with Tau pathology. We present evidence that Tau pathology induces engulfment of excitatory synapses by microglia in a C1q-dependent manner. Moreover, treatment with a C1q-neutralizing antibody reduces synapse removal by microglia and rescues synapse density in Tau-P301S mice.
RESULTS

Tau-P301S Mice Develop Cognitive and Synaptic Deficits and Accumulate Synaptic Phospho-Tau before Overt Neurodegeneration
To determine the molecular mechanisms by which pathological Tau affects synapses, we sought to identify changes in the PSD proteome early in the course of disease in transgenic mice that express the human Tau mutant Tau-P301S (Yoshiyama et al., 2007) . Tau-P301S mice showed age-dependent increase in Tau pathology, as measured by phospho-Tau (AT8) immunoreactivity, especially in the hippocampus starting in the mossy fiber tract at 6 months and spreading throughout the hippocampus by 9 months (Figures 1A and 1B) . AT8 staining was virtually undetectable in nontransgenic (nonTg) brains at all ages. The worsening of AT8 Tau pathology was accompanied by progressive increase in staining of reactive CD68+ microglia and GFAP+ astrocytes in the same brain regions (Figures 1A and 1B) . At 12 months, Tau-P301S mice showed obvious neurodegeneration and clear hippocampal atrophy ( Figure 1A ). By MRI brain scan, the volume of hippocampus in Tau-P301S mice was similar to nonTg mice at 6 and 9 months of age but declined severely by 12 months of age ( Figure S1A ).
We assessed activity of Tau-P301S mice in the open-field assay, as hippocampal lesions are known to induce hyperlocomotion (Le-courtier et al., 2012) . Tau-P301S mice behaved similarly to nonTg mice at 6 and 9 months of age but showed elevated total motor activity at 12 months of age ( Figure S1B ). In the Morris water maze test, which measures spatial learning and memory, 9-month-old Tau-P301S-mice learned more slowly than nonTg controls, traveling a greater distance to the target platform and spending less time in the target quadrant ( Figure S1C ). Electrophysiological analysis of hippocampal brain slices from 9-monthold Tau-P301S mice showed exaggerated short-term synaptic facilitation (increased paired-pulse ratio; PPR), and significantly reduced long-term potentiation (LTP) of excitatory postsynaptic potentials (EPSPs) and population spikes ( Figure S1D ). No significant alterations in PPR and LTP were observed in 4-month-old mice ( Figure S1D ), suggesting that synaptic impairment was driven by the progressive Tau pathology. Based on the above characterization of disease progression in Tau-P301S mice, we performed all subsequent analyses of PSDs at 9 months of age when robust Tau pathology and synaptic dysfunction are present, but prior to overt hippocampal neurodegeneration and atrophy.
Synaptic Enrichment of Specific Tau Species in Tau-P301S Mice
We purified PSDs from the hippocampus of nonTg and Tau-P301S mice and analyzed the nature of Tau species in PSD fractions versus total lysates by immunoblotting. While total Tau was increased in Tau-P301S mice, there was no significant difference in Tau levels in lysates versus PSD fractions within either nonTg or Tau-P301S mice when the total immunoreactivity of all Taubands was quantified ( Figure 1C ). Tau immunoblots of Tau-P301S brain, however, showed a complex banding pattern with marked differences between the PSD and total lysate, suggesting that specific Tau species were enriched in synapses ( Figure 1C ). As expected, overall phospho-Tau levels were highly elevated in Tau-P301S mice compared with nonTg mice. Notably, AT8, AT100, and AT180 antibodies (which recognize phosphoepitopes that are abundant in pathological aggregated and filamentous Tau of human AD) showed an elevated signal in Tau-P301S mice that was markedly enriched in PSD fractions and only weak or undetectable in nonTg mice ( Figure 1D ).
Correlative light-electron microscopy (CLEM) ( Figure S2 ) revealed that hTau was localized throughout neuronal cell bodies and processes in the hippocampal CA1 region (Figures S2A-S2E). hTau was readily detectable in presynaptic termini, often associated with synaptic vesicles, and in the majority (>80%) of postsynaptic compartments close to the PSD ( Figure 1E ). Quantitative measurements of immunogold distribution showed that hTau is most concentrated in the region 50 nm to 250 nm from the synaptic cleft ( Figure 1E ). Virtually no hTau immunogold signal was detected in nonTg brain ( Figure S2A ). When AT8 phospho-Tau antibody was used in immunoEM, the AT8 immunogold particles were often found on dense aggregates (Figures S2F and S2G) , which were also detected in presynaptic termini and in dendritic spines ( Figure 1F ).
Quantitative Proteomics Reveals Molecular Changes in PSDs of Tau-P301S Mice
What happens to the protein composition of PSDs as phospho-hTau protein accumulates in presynaptic and postsynaptic compartments? We looked for changes in the PSD fraction in 9month-old Tau-P301S mice using label-free quantitative mass spectrometry (MS). A total of 1,257 unique proteins were identified in the PSD, of which 76 were significantly decreased and 45 significantly increased in Tau-P301S PSD fractions, relative to nonTg ( Figure 2A ; Table S1 ). Although a number of PSD proteins showed a decline in levels (Table S1) , there was no significant change in the abundance of PSD scaffold molecules such as Figure S1 and S2.
PSD-95, Homer1, and Shank3, which we confirmed in an independent mouse cohort by western blot ( Figure 2B ), suggesting that the core PSD architecture is largely intact in Tau-P301S mice at this age. To validate the MS results, we measured a set of selected proteins in an independent mouse cohort by western blotting and confirmed that Prrt1, an AMPA-receptor-interacting protein, and SynGAP1, a synaptic Ras-GAP, were significantly decreased in Tau-P301S PSDs (Figures 2A and 2B ; Table S1 ). Ezrin, a cross-linker of the membrane-cytoskeleton interface, was increased in the Tau-P301S PSD fractions (Figures 2A and  2B ; Table S1 ). The total hippocampal levels of Prrt1, SynGAP1, and Ezrin were unchanged, suggesting that these proteins are specifically depleted from (Prrt1, SynGAP1) or augmented (Ezrin), in the PSD ( Figure 2B ). By MS, we also identified multiple post-translational modifications of hTau in the PSD, including 22 different phospho-sites, supporting the conclusion that highly phosphorylated Tau is present in the synaptic compartment in Tau-P301S hippocampi (Table S2) .
Gene ontology enrichment analyses ( Figure 2C ) suggest that many of the downregulated biological processes in Tau-P301S PSDs are related to synapse structure and activity and glutamate receptor signaling. Indeed, several AMPA and NMDA receptor subunits were underrepresented in the Tau-P301S PSDs (Table S1 ). Besides these broad processes relating to synapse structure and function, we observed a significant reduction in a set of proteins that regulate small GTPase signaling in Tau-P301S PSDs (Figures 2A and 2C) . Conversely, proteins that showed enrichment in Tau-P301S PSDs are mainly involved in translation and biosynthetic processes. These include ribonucleoproteins and proteins involved in RNA processing, which might be enriched at postsynaptic sites through direct interaction with Tau (Gunawardana et al., 2015) . Particularly striking was that the most highly increased proteins in Tau-P301S PSD fractions are subunits of C1q (Figure 2A ; see below). Given that many genes encoding synaptic proteins are linked to neurological and psychiatric diseases (Bayé s et al., 2011) , we asked whether the differentially abundant proteins in the Tau-P301S PSD fraction are associated with AD or neurodevelopmental and psychiatric disorders. We identified 24 proteins from familial AD or AD genome-wide association studies (GWASs) in the PSD proteome. Cntn1, Rimbp2, and Ctnna2, whose biology is not well understood, were significantly decreased in Tau-P301S PSDs ( Figure 2D ). Interestingly, amyloid precursor protein (APP) was significantly more abundant in Tau-P301S PSD fractions ( Figure 2D ). In addition, we noted that Clusterin/ApoJ, which shows GWAS association with lateonset AD (Harold et al., 2009) , was increased $1.5-fold in Tau-P301S PSDs by MS analysis but did not reach statistical significance ( Figure 2D ; Table S1 ). However, we could confirm by immunoblotting in an independent mouse cohort that Clu/ ApoJ in PSD fractions was $65% increased ( Figure 2B ). As noted previously (Noebels, 2015; Zoghbi and Bear, 2012) , we found that a substantial number of PSD proteins (208/1,257) are associated with the neurodevelopmental disorders epilepsy, autism, and schizophrenia. Notably, there was a significant enrichment of such disease-associated proteins among the decreased proteins in Tau-P301S PSDs ( Figure 2E ; p = 0.0008), indicating that there might be overlapping pathophysiologic mechanisms at the synapse between tauopathies and neurodevelopmental disorders.
As a resource for further data mining, Table S1 contains the quantitative MS data of the PSD proteome for nonTg and Tau-P301S mice and the statistics of every differentially expressed protein as well as their disease association.
Loss of GTPase Regulatory Proteins and Altered Actin Cytoskeleton Could Contribute to Spine Loss in Tau-P301S-PSDs
To test the functional significance of altered levels of PSD proteins in Tau-P301S mice, we focused on the downregulated ''small GTPase-mediated signal transduction'' pathway. This pathway contains a number of GTPase-regulating proteins (Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio; Figure 2A) , where variants in the underlying genes are associated with epilepsy, autism, schizophrenia, or intellectual disability (De Rubeis et al., 2014; Russell et al., 2014; Sadybekov et al., 2017; Shoubridge et al., 2010; Yang et al., 2014) .
Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio are localized in dendritic spines of hippocampal neurons ( Figure S3A ) and enriched in PSD fractions of the mouse hippocampus ( Figure S3B ) (Gao et al., 2011; Myers et al., 2012; Xie et al., 2007) . Corroborating the MS analysis, we confirmed by immunoblotting the significant decrease of PSD levels of Iqgap2, Iqsec2, and Kalirin in 9-monthold Tau-P301S hippocampi ( Figure 3A ). The RhoGEF Trio, which was significantly decreased in the Tau-P301S-PSD by MS analysis (but did not reach the 0.5 log2-fold change cutoff), was also significantly reduced by $30% in Tau-P301S-PSD fractions by immunoblot analysis of an independent cohort (Figures 2A and 3A) . PSD levels of these GTPase regulatory proteins were unchanged in 6-month-old mice ( Figure S3C) . The levels of all tested GTPase-regulating proteins were unchanged in total hippocampal lysates, suggesting that the observed reductions are specific to the postsynaptic compartment.
To examine how depletion of these GTPase-regulatory proteins affects dendritic spines, we used small interfering RNA-(siRNA) mediated knockdown in cultured hippocampal neurons ( Figure S3E ). Neurons incubated with individual siRNAs against Iqgap1, Iqgap2, Iqsec2, Kalirin, or Trio showed 30%-50% decreased spine density, while siRNA against Iqsec3, which was not changed in Tau-P301S PSDs, had no effect on spine density ( Figure 3B ). A protein-protein interaction analysis identified that Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio act in a highly interconnected network regulating the Rho family of GTPases, which in turn controls actin dynamics ( Figure S3D ). Thus, we hypothesized that knockdown of the GTPase regulators caused loss of spines via dysregulation of the postsynaptic actin network and investigated whether pharmacological stabilization of filamentous actin (F-actin) would stabilize spines. Neurons that had been treated with siRNAs for 5 days in vitro (DIV14+5), were incubated with fresh siRNAs and the F-actin stabilizing agent phallacidin for another 2 days. Phallacidin had no effect on spines in control cultures but restored spine density in neurons treated with siRNAs targeting Iqsec2, Kalirin, Trio, or Iqgap1 and Iqgap2, or even led to spine density greater than control neurons ( Figure 3C ). To probe the state of postsynaptic actin polymerization in vivo, we stained F-actin (using phalloidin) and the postsynaptic marker Homer1 in the hippocampal CA1 region in nonTg and Tau-P301S mice. The fluorescence intensity of phalloidin signal that colocalized with Homer1 clusters (a measure of the amount of postsynaptic F-actin) was reduced $30% in Tau-P301S versus nonTg mice ( Figure 3D ).
Together, these results highlight that the synaptic GTPaseregulating proteins Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio are specifically decreased in the PSD compartment of Tau-P301S mice, which can lead to dysregulation of the actin cytoskeleton and potentially contribute to the spine loss seen in AD and other tauopathies.
Accumulation of Complement C1q at Synapses in Tau-P301S Mice
Among the most highly upregulated proteins in PSD fractions of Tau-P301S hippocampi was C1q (Figure 2A ; Table S1 ). By western blotting of a different cohort of mice, we confirmed that C1q was greatly increased (with high inter-animal variability) in PSDs of 9-month-old Tau-P301S hippocampi and barely detectable in the nonTg PSD ( Figure 4A ). C1q levels were also increased in hippocampal lysates from Tau-P301S mice, although to a lesser degree than in PSD fractions. These biochemical data suggest that C1q accumulates at synapses in the Tau-P301S brain before overt neurodegeneration has taken place.
Stimulated emission depletion (STED) super-resolution microscopy of brain sections, co-stained for C1q and presynaptic (Synapsin) and postsynaptic (PSD-95) markers ( Figure 4B Figure S4A ). The percentage of C1q-labeled synapses in hippocampal CA1 was much higher in Tau-P301S (18.2% ± 0.9%) than in non-Tg brains (8% ± 1.6%) at 9 months of age ( Figure 4C ), corroborating the biochemical results from PSD isolations. Moreover, using CLEM with immunogold labeling for C1q, we observed increased density of synaptic C1q labeling in the dentate gyrus (DG) of Tau-P301S mice (Figure 4D) . C1q immunogold particles were not localized in the synaptic cleft or at the synapse proper, but rather were found in perisynaptic regions associated with the pre-and postsynaptic membranes. Intriguingly, the increase in synaptic C1q labeling in Tau-P301S mice was mainly driven by augmented postsynaptic C1q, as the percentage of presynaptic labeling by C1q was only slightly increased between Tau-P301S and nonTg mice ( Figure 4D ).
Although C1q levels in the PSD were highly variable between individual Tau-P301S animals ( Figure 4A ), there was a strong positive correlation between the amount of C1q and the amount of AT8 phospho-Tau in PSD preparations from different Tau-P301S mice ( Figure 4E ), consistent with the idea that Tau pathology causes C1q accumulation and that C1q associates with synapses that have been affected by phospho-Tau. Importantly, antibodies against PSD-95 (but not Gephyrin, the scaffold of GABAergic synapses) co-immunoprecipitated C1q and hTau from hippocampal lysates, confirming that C1q and Tau are specifically in the PSD-95 complex associated with excitatory synapses ( Figure 4F ). In Tau-P301S hippocampi, only the higher-migrating phosphorylated Tau band co-immunoprecipitated with PSD-95 (Figure 4F) , further suggesting that it is the pathological phospho-Tau that interacts with the PSD. The amount of C1q co-immunoprecipitated with PSD-95 was greater from Tau-P301S than from nonTg hippocampus and mirrored the amount of co-immunoprecipitated phospho-Tau, supporting the idea that C1q associates with phospho-Tau-containing synapses ( Figure 4F) . During disease progression, C1q signal was prominent in the hippocampus already at 6 months, especially in the DG and CA2/3 region, in both Tau-P301S and nonTg mice ( Figure S4B ). In nonTg mice, hippocampal C1q immunostaining stayed roughly constant from 6-12 months of age, whereas in Tau-P301S mice it increased in intensity at 9 and 12 months (Figure S4B) . Increased hippocampal C1q immunoreactivity lagged slightly behind phospho-Tau pathology insofar as AT8 staining emerged above nonTg levels by 6 months of age and plateaued at 9-12 months ( Figures 1A and 1B) , whereas C1q intensity rose above nonTg levels only at 9 months and continued to climb through 12 months of age ( Figure S4B ).
Increased C1q levels have recently been reported in mouse models of b-amyloidosis (Hong et al., 2016a) , so we compared the PSD level of C1q present in Tau-P301S mice to that of PS2/APP transgenic mice (expressing mutant Presenilin 2 [PS2] N141I and APP Swedish mutation [K595N/M596L]) at 9 months of age when there are abundant amyloid plaques in the brain (Richards et al., 2003) . The average level of C1q in the PSD of Tau-P301S mice was elevated $9-fold above nonTg controls, whereas it was increased only 2-to 3-fold in the PSD of PS2/APP mice ( Figure 4G) . Thus, at least in these mouse models, Tau pathology seems to more potently induce C1q accumulation at synapses than does b-amyloidosis. There was slightly more See also Figure S5 and Table S3 .
microgliosis associated with P301S-tauopathy than with PS2/APP amyloidosis ( Figure S4 ), and given that microglia are a major source of C1q production in the brain, it is possible this difference might contribute to the greater C1q accumulation in the Tau-P301S brain.
Complement Is Increased and Associated with Synapses in Human AD Brains Does C1q also accumulate and associate with synapses in human brain tissue from AD patients? Although variable between individuals, mean levels of C1q in superior frontal gyrus (SFG) lysates were increased $1.5-fold in patients with a diagnosis of early-stage AD (EAD) and $2-fold elevated in patients with autopsy-confirmed AD ( Figure 5A ; Table S3 ). Like in the Tau-P301S mice, C1q levels were significantly correlated with phospho-Tau (AT8) levels ( Figure 5B ). We also analyzed the downstream complement factor C3, which was unchanged in SFG lysates of EAD patients but increased $2-fold in AD patients ( Figure 5A ) and significantly correlated with C1q levels among the individuals ( Figure 5C ).
We isolated PSDs from a small number of SFG tissues from AD patients and assessed whether phospho-Tau and C1q are biochemically associated with synapses. AT8 immunoreactivity was enriched in PSD fractions compared to total lysates from AD brains, similar to Tau-P301S mice. C1q was elevated in total lysate and highly enriched in the PSD fractions from EAD as well as AD patients ( Figure 5D ). These data indicate that C1q is enriched in human AD brains and appears to be associated with synapses in EAD and AD.
We measured the expression of complement genes (all genes from the complement pathway as well as complement regulatory proteins and receptors) by RNA sequencing of fusiform gyrus from normal controls and autopsy-confirmed AD patients and cross-checked it with an independent microarray dataset from temporal cortex (Friedman et al., 2018; Webster et al., 2009) (Figure S5A) . Expression of the complement gene set was significantly increased in AD patients in both data sets ( Figure S5B ). The transcriptomic data supports the idea that the complement pathway is elevated in AD brains.
Microglial Engulfment of Synapses Is Increased in P301S-Transgenic Mice
Labeling of synapses by C1q is thought to lead to engulfment by microglia, which might be a driver of synapse loss (Hong et al., 2016a) . Indeed, we detected a 25%-30% reduction in synapse density (as defined by Synapsin or PSD-95 puncta density) in the CA1 region of 9-month-old Tau-P301S mice ( Figure S6A ). Synapse density was similar between Tau-P301S and nonTg animals at 6 months ( Figure S6A) , an age when C1q and AT8 staining show little change between nonTg and Tau-P301S hippocampus (Figure 1B; Figure S4B ). Consistent with a slight loss of synapses at 9 months, the protein yield of biochemically isolated PSDs was $20% lower from Tau-P301S hippocampi ( Figure S6B ).
To investigate whether microglia engulf neuronal material in disease, we immunoisolated CD11b + microglia from the forebrain of nonTg and Tau-P301S mice by flow cytometry (Srinivasan et al., 2016) and analyzed the sorted microglia by western blotting. In these highly purified microglia, we detected low levels of Synaptophysin and PSD-95 in nonTg mice, which were increased $3to 4-fold in Tau-P301S mice ( Figure 6A ). When normalized to actin, which was consistently elevated in the microglia prep purified from Tau-P301S brains, Synaptophysin and PSD-95 levels were increased only $1.5 fold ( Figure 6A ), suggesting that the increase can be explained in large part by an increased number and/or size of microglial cells in Tau-P301S mice. Tau was readily detectable in microglia isolated A B Figure 6 . Microglial Engulfment of Synapses in Hippocampus of Tau-P301S Mice (A) Representative immunoblots for the indicated proteins in Iba1 + FACS-sorted microglia from forebrain of nonTg and Tau-P301S mice. Quantitation of Synaptophysin (Sphysin) and PSD-95 immunoblots, normalized to nonTg microglia, or normalized to actin and the average of nonTg microglia. Each dot represents one mouse. (B) 3D rendering of confocal stacks of CD68+ microglial lysosomes and engulfed PSD-95 or Synapsin puncta in CA1 region of nonTg and Tau-P301S mice at 6 or 9 months of age. Quantitation of relative number of Synapsin and PSD-95 puncta in CD68 + lysosomes normalized to nonTg mice. 4-6 animals were used for microglial engulfment analysis, each dot is data from one microglia. Scale bar, 1 mm. Histograms and error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; two-way ANOVA with Bonferroni's multiple comparisons test. See also Figure S6 . from Tau-P301S, but not nonTg brain. NeuN, a neuronal marker found in the nucleus, was undetectable in any of the purified microglia ( Figure 6A ), suggesting that microglia engulf synapses and perhaps not neuronal soma and arguing against a non-specific contamination of the microglial prep by neuronal cells.
To measure synapse engulfment by microglia more directly, we used immunofluorescence confocal microscopy to quantify PSD-95 and Synapsin puncta present within microglial lysosomes (visualized using microglial lysosome marker CD68) in brain sections ( Figure 6B ). In line with the biochemical data from isolated microglia, we observed an $2-fold increase in the number of PSD-95 and Synapsin puncta that are located within microglial lysosomes in hippocampal CA1 region from Tau-P301S mice at 9 months, but not at 6 months, of age ( Figure 6B ). Taken together, the biochemical and imaging data show that there is increased microglial engulfment of synapses (both pre-and postsynaptic compartments) in Tau-P301S mice at 9 months of age, temporally correlating with accumulation of C1q and a drop in synapse density.
C1q-Blocking Antibody Decreases Microglial Synapse Engulfment In Vitro
Based on the above findings, we hypothesized that C1qdependent microglial engulfment of synapses is a crucial mechanism leading to synapse loss in tauopathy. Would inhibition of C1q function be sufficient to prevent synapse removal by microglia? To test this, we used a C1q-blocking antibody, which potently blocked C1q binding to cultured neurons (Figures S7A and S7B ). We first tested whether the anti-C1q antibody could decrease microglial synapse engulfment in vitro. Primary rat hippocampal neurons were transfected with Tau-P301S at DIV7; a week later (DIV14), they were co-cultured with microglia (3:1 neuron:microglia ratio) for another 3 days. Compared with dendrites of neurons cultured in absence of microglia, synapse density, as measured by PSD-95 clusters, was reduced by $30% on ''microglia-proximal'' dendrites (overlapping or in contact with Iba1 + cells) but was unchanged on ''microglia-distant'' dendrites (>30 mm separated from Iba1 + cells) ( Figure S7C ), suggesting that removal of synapses is mediated through close neuron-microglia interaction rather than soluble neurotoxic factors secreted by microglia. To test whether C1q is important for depletion of synapses by microglia, we added the C1q-blocking antibody or IgG isotype control at the same time as microglia to the neurons ( Figure 7A ). C1q-blocking antibodies, but not IgG isotype control, prevented the loss of PSD-95 puncta along microglia-proximal dendrites (Figures 7A and 7B) . The density of Gephyrin clusters was not affected by microglia or by addition of C1q antibodies, further suggesting that microglia selectively remove excitatory synapses without damaging the dendrite (Figures 7A and 7B) . In control neurons expressing GFP only, PSD-95 puncta density was not significantly affected by co-culture with microglia ( Figure 7C ), indicating that synapse pruning by microglia is dependent on Tau-P301S expression. In line with the hypothesis that synapse removal involves C1q, the percentage of C1q-labeled synapses was significantly higher on neurons transfected with Tau-P301S than on control GFP-expressing neurons in neuron-microglia cultures (Figures 7D and 7E) . Addition of exogenous C1q also resulted in more C1q labeling of synapses on Tau-P301S transfected neurons ( Figure 7F ). Thus, overexpression of Tau-P301S in neurons appears to enhance the binding of C1q to synapses. 
C1q-Blocking Antibody Decreases Microglial Synapse Engulfment and Rescues Synapse Density in Tau-P301S Mice
To determine whether C1q-blocking antibodies can prevent synapse engulfment by microglia and rescue synapse loss in vivo, we injected C1q-blocking or isotype control antibodies into the right dorsal hippocampus of 9-month-old Tau-P301S mice and analyzed the animals 5 days later ( Figures 8A and 8B) . The injected anti-C1q antibodies were present throughout the ipsilateral hippocampus and, to a lesser extent, the contralateral side ( Figures 8A and 8B) . The distribution pattern of anti-C1q antibody was similar to that of C1q protein, suggesting that the antibody bound the target ( Figure 8A ). Control IgG showed diffuse staining in hippocampus and cortex (ipsilateral > contralateral) with no specific colocalization with C1q ( Figures 8A and 8B) . In brains injected with anti-C1q, the intensity of C1q staining was reduced in the ipsilateral hippocampus, while control IgG injection had no effect ( Figures 8A and 8B) . In the ipsilateral CA1 region, the C1q-blocking antibody resulted in $50% reduction in PSD-95 or Synapsin puncta within microglial lysosomes, as compared to control IgG (Figure 8C ), suggesting that C1q neutralization inhibited microglial synapse engulfment in Tau-P301S brains. Remarkably, we measured a slight but significant increase in PSD-95 and Synapsin puncta density in CA1 at 5 days after injection of C1q blocking antibody, relative to control IgG ( Figure 8D ). Although electrophysiological properties of acute hippocampal slices (including LTP) were not changed at 5 days after injection of C1q antibodies ( Figure S8 ), our results demonstrate that C1q antibodies can reduce synapse removal by microglia and lead to a recovery of synapse density in cultures and in vivo.
DISCUSSION
Synapse loss is one of the best correlates of cognitive deficits in AD, but its underlying molecular mechanism is poorly understood Spires-Jones and Hyman, 2014) . Synapse loss correlates more closely with Tau pathology in the AD brain than with the load of amyloid plaque, which starts accumulating many years prior to onset of disease symptoms (Weiner et al., 2015) . Moreover, there is mounting evidence that Tau pathology and neurotoxicity is, at least in part, downstream of amyloidosis in the pathogenic cascade underlying AD ( 2015; Roberson et al., 2007) . For these reasons, we focused on tauopathy and the molecular mechanisms by which tauopathy drives synapse loss. At a disease stage before obvious neurodegeneration, MS analysis showed that whereas the core architecture of the PSD, which is built around scaffolds like PSD-95 (Chen et al., 2011; Sheng and Hoogenraad, 2007) , appears largely intact, multiple changes occur in the hippocampal PSD proteome. The biochemical analysis of the PSD provides only a view of the ''average'' synapse and so may hide the heterogeneity of changes in individual PSDs that occur in response to tauopathy. With that caveat noted, PSDs of tauopathyaffected neurons are depleted of a specific set of intracellular signaling proteins with known postsynaptic functions (small GTPase regulators) while accumulating an extracellular protein involved in innate immunity (complement C1q). Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio regulate Rho family GTPases and hence play a pivotal role in the dynamics of the F-actin cytoskeleton in spines (Spence and Soderling, 2015) . Loss of these GTPase regulators could provide a molecular explanation for why actin is compromised in spines of AD patients (Kommaddi et al., 2018) . Because these proteins normally regulate dendritic spine integrity and synapse density as well as synaptic signaling, the PSD-specific depletion of Iqgap1, Iqgap2, Iqsec2, Kalirin, and Trio could contribute to synaptic dysfunction and cognitive impairment in AD, as evidenced by synaptic and/or cognitive deficits upon deletion of these genes (Cahill et al., 2009; Elagabani et al., 2016; Gao et al., 2011; Herring and Nicoll, 2016) . It is intriguing that this set of GTPase regulators, as well as a disproportionate number of the other downregulated PSD proteins in tauopathy, are genetically linked to neurodevelopmental disorders such as autism spectrum disorder and schizophrenia (Fromer et al., 2014; Li et al., 2016; Noebels, 2015; Shoubridge et al., 2010; Zoghbi and Bear, 2012) . Thus, we speculate that, despite different etiologies and disparate ages of onset of AD versus neurodevelopmental disorders, overlapping alterations in biochemical and cell biological signaling mechanisms may occur at the synapse to mediate the synaptic/circuit dysfunction and cognitive symptoms that are in common between neurodegenerative and neurodevelopmental diseases. Further underscoring this ''shared mechanism'' concept is the recent discovery that genetic variants of the complement component C4A locus (which are associated with elevated expression of C4) increase the risk of schizophrenia (Sekar et al., 2016) , and that complement may play a role in synapse elimination in neurodevelopmental disorders (Neniskyte and Gross, 2017; Zoghbi and Bear, 2012) , as well as in neurodegeneration.
Our unbiased identification of C1q accumulation in Tau-P301S PSDs, the close correlation between synaptic levels of C1q and phospho-Tau, and the high-resolution localization of C1q at excitatory synapses by light microscopy (LM) and electron microscopy (EM) provide compelling evidence that tauopathy induces the C1q tagging of synapses. Given that C1q is a secreted protein produced mainly by microglia, and microglia engulf synapses more avidly in the Tau-P301S brain, our study points to a critical microglia-neuron interaction in the synapse loss of tauopathy. We also found elevated C1q in AD patient brains, not only in bulk tissue, but also in purified PSD fractions, consistent with synaptic tagging by C1q in AD. Our findings support the idea that the complement pathway, which plays a role in synaptic pruning during development in various regions of the brain, is re-activated in neurodegenerative disease (Stephan et al., 2012) .
Some interesting points are revealed by this study.
(1) Tauopathy seems more potent than amyloidosis in inducing C1q accumulation at synapses; this difference correlates with the strong neurodegeneration phenotype of Tau-P301S mice (see Figure 1 ) versus the minimal neurodegeneration phenotype of PS2/APP transgenic mice (Richards et al., 2003) and supports the idea that Tau-mediated complement activation is a key mechanism in the synapse loss and neurodegeneration of AD. However, while tauopathy seems to be sufficient to induce the C1q tagging of synapses, it may not be absolutely necessary for this outcome, as synaptic C1q buildup is also stimulated by amyloidosis and can occur in early AD brain tissue prior to the detection of AT8-immunoreactive phospho-Tau (see Figure 5D ). (2) Although conspicuously localized at synapses in tauopathy mice, C1q is also deposited at non-synaptic sites on neurons and possibly other cells suggesting that other structures could be targets of microglial engulfment or complement-mediated damage.
How does C1q recognize Tau-damaged synapses, and is there a link between changes in the PSD composition and postsynaptic C1q binding? During development, complementdependent synaptic pruning by microglia is modulated by synaptic activity such that active synapses are preserved and less active synapses are removed (Schafer et al., 2012) , implying that complement can ''detect'' morphofunctional changes at the synapse. In principle, Tau-driven changes in the PSD could lead to a signal for recruitment of C1q. In this context, it will be critical to identify the synaptic receptor(s) for C1q. The co-immunoprecipitation of C1q with PSD-95 indicates that C1q associates with the PSD-95-scaffolded complex, where it might bind to a transmembrane protein of as yet unknown identity. Alternatively, pathogenic Tau might trigger the exposure of lipid molecules like phosphatidylserine, a well-characterized ''eat me'' signal and C1q ligand on apoptotic cells (Païdassi et al., 2008) , perhaps through local non-lethal activation of caspase-3 in spines (Ert€ urk et al., 2014; Gyö rffy et al., 2018) .
We observed increased synaptic material engulfed by microglia in Tau-P301S mice, and this engulfment could be reduced with a C1q-blocking antibody. A key question is whether microglia engulf intact synapses or simply phagocytose synaptic debris that has been shed from injured neurons. Our neuron-microglia co-cultures suggest that, at least in vitro, microglia are able to remove excitatory synapses without apparent damage to the dendrite or loss of inhibitory synapses. Recently, using light sheet fluorescence microscopy and CLEM, microglia have been shown to ''nibble'' and phagocytose presynaptic, but not postsynaptic, terminals during development (Weinhard et al., 2018) . In this context, it is interesting that we detect C1q in normal brain mostly at presynaptic locations, whereas the buildup of C1q in Tau-P301S brain takes place mainly at postsynaptic sites, where it may promote the removal of Taudamaged postsynapses and spines. The rescue of synapse density following anti-C1q treatment of Tau-P301S mice is more consistent with a role of microglia in removing viable synapses rather than simply clearing debris.
It is remarkable that a single injection of C1q-blocking antibodies not only reduced microglial engulfment of synapses in vivo but also enhanced synapse density 5 days post injection. This rescue of synapse number suggests an ongoing dynamic turnover of synapses in the Tau-P301S brain that can be rebalanced in a favorable direction by neutralization of C1q. Despite amelioration of synapse density, a single injection of anti-C1q did not improve LTP. As revealed in our proteomic analysis, however, there are multiple other changes induced by tauopathy in the PSD that might not be fixed by neutralization of C1q. More optimistically, perhaps longer treatment with C1q antibodies is needed to obtain benefit beyond the structural saving of synapses. The above notwithstanding, complement activation and synapse loss seems to be a feature of multiple neurological diseases, including progranulin-deficient frontotemporal dementia (Lui et al., 2016) , virus-induced memory impairment (Vasek et al., 2016) , glaucoma (Stevens et al., 2007) , and CNS lupus (Bialas et al., 2017) ; therefore, a therapeutic approach that blocks C1q and microglial eating of synapses is worth exploring for a range of neurodegenerative disorders.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 1 mg/ml Laminin, 0.5 mM Glutamax. Human NSCs were plated to PDL and Laminin-coated 96 well plates at 40,000/cm 2 in differentiation media. 50% of media was changed biweekly for the duration of the experiment. After culturing for 6-8 weeks, the neurons were used for experiments.
METHOD DETAILS
Brain immunohistochemical and immunofluorescence staining Mice were deeply anesthetized and transcardially perfused with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in PBS for fixation. Brains were post-fixed in 4% PFA overnight, then cryoprotected in 30% sucrose. Alternatively, the right hemi-brain was drop fixed for 48 h at 4 C in 4% PFA for immunohistochemistry and the left forebrain was frozen and later homogenized. Brains were either embedded in a solid matrix and sectioned at 30 mm by NeuroScience Associates or were sectioned in house at 35mm using a sliding microtome. Sections were preserved in cryoprotectant (30% glycerol, 30% ethylene glycol, and PBS) and stored at À20 C. For fluorescent immunostainings, free-floating sections were rinsed in PBS, followed by PBS with 0.2% Triton X-100 (PBST), blocked with blocking buffer (5% goat serum, 5% bovine serum albumin (BSA) in PBST) and incubated overnight with primary antibodies in blocking buffer. For PSD-95 immunostaining, sections were pre-incubated with 1% Triton X-100 to make the PSD accessible before staining. Secondary antibodies in blocking buffer were incubated for 2-3h at room temperature, extensively washed in PBST and PBS and mounted using ProLong Diamond medium (ThermoFisher).
For 3'-Diaminobenzidine (DAB) immunostaining, free-floating sections were rinsed in Tris-buffered saline (TBS), treated with hydrogen peroxide in TBST (TBS plus Triton X-100), and blocked with TBST plus goat serum before overnight incubation at room temperature with primary antibody diluted in TBST. Binding was detected with biotin-conjugated secondary antibodies followed by avidin-biotin-HRP complex (Vectastain elite ABC kit, Vector Laboratories) and developed with diaminobenzidine tetrahydrochloride. CD68-immunostained sections were counterstained with a Nissl stain (0.05% thionine/0.08 M acetate buffer, pH 4.5).
Tissue imaging and analysis
For total immunofluorescence analysis, brains sections were scanned on a Hamamatsu NanoZoomer S60. Mean fluorescence intensity of region of interest (ROI) was measured in MATLAB (MathWorks). Histological samples were imaged using the Leica SCN400 system equipped with automated loader and software (Leica Microsystems). Quantification of DAB staining and enlarged dark cluster areas was performed using morphometric-based methods in MATLAB, as previously described (Le Pichon et al., 2013) . Color thresholds in RGB and HSV space were used to identify the positive staining. The percentage DAB-positivity for hippocampal ROIs were calculated by normalizing the positive pixel area to section area.
All sections were averaged from three to seven sections/animal. All images, segmentation overlays, and data were reviewed by a pathologist.
For microglia engulfment analysis, brain sections were imaged on the Zeiss LSM 780 taking up to 35 z-stacks at 0.39 mm steps with a 100x oil objective. CD68-positive lysosomes were 3D-reconstructed using the surface rendering function in Imaris 8.3 and Synapsin or PSD-95 puncta inside the CD68+ lysosomes were quantified. 6-9 microglia within the hippocampal CA1 region were analyzed per mouse.
For STED super-resolution imaging, brain sections were stained for Synapsin, PSD-95 and C1q and hippocampal CA1 regions were imaged on a Leica SP8 STED 3x microscope using a 100x objective at a pixel size of 15 nm/pixel. Images were deconvoluted using the Huygens package and distanced between the cluster centers were measured in ImageJ (NIH). For C1q-Synapsin co-localization, STED images were analyzed using the ImageJ plugin ComDet 0.3.6.1 and automatically detected clusters were considered as co-localized if distance between spot centers was % 200 nm.
Immunoelectron microscopy (immunoEM) and analysis
Fixed brains were cut in 1 mm thick sagittal slices. Whole brain slices as well as isolated, $1 mm 3 blocks of hippocampus tissue were then processed for immunoEM according to the Tokuyasu method (Slot and Geuze, 2007) . Briefly, tissue slices and blocks were rinsed in PBS and PBS with 0.15% glycin, embedded in 12% gelatin in 0.1 M PB and cryoprotected with 2.3 M sucrose in 0.1 M PB. Hippocampal tissue blocks were mounted in random orientation on aluminum pins and frozen in liquid nitrogen. From the brain slices, the hippocampus was excised and cut in an anterior and posterior half, each $1 mm 3 in size. Each block was then mounted on an aluminum pin such that sagittal hippocampus sections could be cut with known ventral-dorsal orientation, and frozen in liquid nitrogen.
From these blocks, semithin cryosections, 300-400 nm thick, were cut at -100 C, placed on glass coverslips, labeled with primary antibodies, fluorescent secondary antibodies and DAPI, and examined in a DeltaVision wide-field fluorescence microscope. Ultrathin cryosections for immunoEM were cut at -120 C, placed on copper carrier grids and sequentially incubated on PBS at 37 C to dissolve gelatin, then at room temperature on primary and secondary antibody solutions, followed by 10 nm Protein A-gold particles (Cell Microscopy Core, University Medical Center Utrecht, the Netherlands). Incubation times were 1 h at room temperature for Tau-13, AT8 and secondary antibodies, and overnight at 4 C for C1q clone 4.8 antibodies. Blocking solutions contained either BSA, or a mixture of fish skin gelatin and acetylated BSA (BSA-c, from Aurion). Final staining of the sections was performed with uranyl acetate (UAc) followed by a UAc-methylcellulose mixture. For correlative light-electron microscopy (CLEM) (van Rijnsoever et al., 2008) , sections on grids were additionally labeled with a fluorescent secondary antibody and DAPI, imaged in a DeltaVision fluorescence microscope, and subsequently rinsed and contrasted with UAc and UAc-methylcellulose for electron microscopy.
For the quantitative analysis of the distribution of Tau-P301S in the synapse, the CA1 region was retraced using CLEM images of Tau-13 immunogold-labeled ultrathin sagittal cryosections of 3 mice per genotype. All gold particles labeling Tau-P301S in axon terminus and spine of 20-24 synapses per Tau-P301S mouse were counted and their distance to the synaptic membranes was measured. The distances of all Tau-13 gold particles were pooled, ranked in 30 nm-classes, and the frequencies, divided by the total number of synapses, were plotted.
For the quantitative analysis of the presence of C1q at the synapse, the molecular layer from the dentate gyrus region was retraced using CLEM images of C1q immunogold labeled, ultrathin sagittal cryosections of 3 mice per genotype. Per mouse, 69-108 synapses were systematically screened and per synapse the presence of C1q immunogold particles was scored as either on presynaptic or postsynaptic or on both pre-and postsynaptic compartments.
FACS-sorting of microglia
Microglia were isolated from nonTg and Tau-P301S mouse forebrains and quality controlled as described previously (Srinivasan et al., 2016) . All steps were carried out at 4 C. Briefly, after perfusion with ice cold PBS, cortex and hippocampi were dissected and triturated to single cell suspension. After obtaining the cell pellet after Percoll gradient step, cells were resuspended in 1 ml of Hibernate A-LF and incubated with Cd11b-APC (BD Pharmingen, clone M1/70, #562690) at 1:200. Cells were then washed and resuspended in 4 ml of Hibernate together with 2 ml of DAPI (1mg/ml). Animals were always processed in pairs (1 nonTg and 1 Tau-Tg) and sorted simultaneously in two BD FACS ARIA sorters. Myeloid cells (DAPI -:CD11b + ) were collected, pelleted at 300xg, 5 min and lysated in 100 ml lysis buffer (50 mM Tris, 150 mM NaCl, 1% TritonX-100, 0.2% SDS) supplemented with protease inhibitors (cOmplete mini, Roche). Cell debris was pelleted (10,000g, 5 min) and equal volumes were used for Western blotting.
Brain slice electrophysiology 400 mm thick slices of hippocampus were prepared with a vibrating sectioning system (Leica, Germany). Slices were recorded while bathed in oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM): 127 NaCl, 2.5 KCl, 1.3 MgSO 4 , 2.5 CaCl 2 , 1.25 Na 2 HPO 4 , 25 NaHCO 3 , and 25 glucose. During slice preparation ice-cold ACSF was used with the MgSO4 concentration elevated to 7 mM, NaCl replaced with 110 mM choline, and with the addition of 11.6 mM Na-ascorbate and 3.1 mM Na-pyruvate. Standard field recordings were performed as previously described (Hanson et al., 2013) . Schaffer collateral inputs were electrically stimulated and EPSPs and population spikes were recorded from stratum radiatum and stratum pyramidale of CA1, respectively. LTP was induced using 1, 2, or 3 bouts of burst stimulation (separated by 20 s), each burst consisting of 5 pulses at 100 Hz.
Stereotaxic antibody injection
The blocking anti-C1q antibody was produced using the variable domain sequences of the previously described anti-C1q M1 antibody (Hong et al., 2016a ) on a mouse IgG2a backbone with the effector-attenuating substitutions L234A, L235A, and P329G (Lo et al., 2017) . 9-months-old female mice were anesthetized with 3% isoflurane and placed on a stereotaxic apparatus (Stoelting) for surgery. All injections were performed with a 10 ml syringe (Hamilton Company) with a pulled glass pipette tip glued to the end of needle, and a syringe pump (Stoelting Quintessential stereotaxic injector). The injection coordinate was 1.25 mm anterior, À1.82 mm lateral, 1.75 mm ventral to bregma. 2 ml of anti-C1q or isotype control antibody (both 28 mg/ml) were injected at a rate of 0.5 ml/min. The needle was removed 2 minutes after completion of the injection and mice were put back in their cage for 5 days before analysis.
Brain MRI
Longitudinal MRI study was performed on Tau-P301S and nonTg female mice (n=10 each group) by imaging animals at 6, 9 and 12 months of age using a 9.4T Varian/Agilent (Agilent Technologies) system with a 30 mm inner-diameter transmit/receive volume coil. The animals were anesthetized using 3% isoflurane and placed in a custom-built head holder with a tooth bar. During imaging, anesthesia was maintained at 1.5% isoflurane. Rectal temperature was monitored and maintained at 37 ± 1 C using a feedback system with warm air (SA Instruments). T2-weighted images were acquired using a multi-spin echo sequence with TR=6000 ms, TE ranged from 10 -80 ms for 8 echoes with a spacing of 10 ms, 56 axial slices of 0.3 mm, FOV 19.2 mm x 19.2 mm, matrix size 128 x 96 (zero-filled to 128 x 128), 2 signal averages, with a scan time of 19 min.
Behavioral tests Locomotor activity
The experimental room was illuminated, providing $300 lux in the middle of the locomotor chambers. PAS open-field recording systems (San Diego Instruments) consisted of transparent thermoplastic cages (width, 40.5 cm; length, 40.5 cm; height, 38 cm) surrounded by a locomotor frame and a rearing frame fitted with infrared beams to record horizontal locomotor activity (3 cm above the floor) and rearing activity (7.5 cm above the floor), respectively. The total number of beam breaks for both locomotor activity and rearing was calculated for a total of 15 min.
